Corrigendum to “From Prohibited to Prescribed: The Rescheduling of MDMA and Psilocybin in Australia”
No abstract is available for this record.
Bibliographic context
- Journal
- Drug Science Policy and Law
- Date
- 2026-05-31
- Source
- OpenAlex
- PubMed
- Unavailable
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
Advancing treatment paradigms: the role of psilocybin in managing major depressive disorderAnnals of Medicine and Surgery · 2025-11-23Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use DisorderPsychedelic Medicine · 2024-11-24Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary FindingsPsychedelic Medicine · 2023-11-30Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-05-31Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-05-03India’s Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric TherapeuticsIndian Journal of Psychological Medicine · 2026-02-04Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 StudyPsychedelic Medicine · 2025-12-22